vigabatrin has been researched along with Nerve Degeneration in 5 studies
Nerve Degeneration: Loss of functional activity and trophic degeneration of nerve axons and their terminal arborizations following the destruction of their cells of origin or interruption of their continuity with these cells. The pathology is characteristic of neurodegenerative diseases. Often the process of nerve degeneration is studied in research on neuroanatomical localization and correlation of the neurophysiology of neural pathways.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The toxic effect of gamma-vinyl-GABA was mimicked by a 24-h treatment with GABA (100 microM) and the GABA(A) receptor agonist, muscimol (10 microM), but not the GABA(B) receptor agonist, baclofen (10 microM)." | 1.31 | GABA(A)-mediated toxicity of hippocampal neurons in vitro. ( Lukasiuk, K; Pitkänen, A, 2000) |
| "Vigabatrin has been recommended as a treatment for some forms of childhood epilepsy; therefore, further studies are needed to assess the risks in children." | 1.30 | Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain. ( Del Bigio, MR; Seshia, SS; Sidhu, RS; Tuor, UI, 1997) |
| "Kainic acid (KA)-induced convulsions are accompanied by histopathological changes that are most prominent in the temporal lobe structures." | 1.29 | Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage. ( Halonen, T; Kotti, T; Miettinen, R; Riekkinen, PJ; Toppinen, A; Tuunanen, J, 1995) |
| "Vigabatrin has been shown to protect against hippocampal neuronal cell death in experimental models of epilepsy." | 1.29 | Treatment with antiepileptic drugs: possible neuroprotective effects. ( Pitkänen, A, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (20.00) | 18.7374 |
| 1990's | 3 (60.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Halonen, T | 1 |
| Kotti, T | 1 |
| Tuunanen, J | 1 |
| Toppinen, A | 1 |
| Miettinen, R | 1 |
| Riekkinen, PJ | 1 |
| Pitkänen, A | 2 |
| Sidhu, RS | 1 |
| Del Bigio, MR | 1 |
| Tuor, UI | 1 |
| Seshia, SS | 1 |
| Lukasiuk, K | 1 |
| Persson, L | 1 |
5 other studies available for vigabatrin and Nerve Degeneration
| Article | Year |
|---|---|
Alpha 2-adrenoceptor agonist, dexmedetomidine, protects against kainic acid-induced convulsions and neuronal damage.
Topics: Adrenergic alpha-Agonists; Adrenergic alpha-Antagonists; Animals; Anticonvulsants; Disease Models, A | 1995 |
Treatment with antiepileptic drugs: possible neuroprotective effects.
Topics: Animals; Anticonvulsants; Epilepsy, Temporal Lobe; gamma-Aminobutyric Acid; Hippocampus; Humans; Ner | 1996 |
Low-dose vigabatrin (gamma-vinyl GABA)-induced damage in the immature rat brain.
Topics: 4-Aminobutyrate Transaminase; Animals; Anticonvulsants; Apoptosis; Brain; Brain Damage, Chronic; Enz | 1997 |
GABA(A)-mediated toxicity of hippocampal neurons in vitro.
Topics: Animals; Anticonvulsants; Bicuculline; Cell Survival; Cells, Cultured; Epilepsy; Female; Fetus; GABA | 2000 |
CSF soluble proteins and vigabatrin.
Topics: Aminocaproates; Animals; Anticonvulsants; Brain; Brain Chemistry; Cerebrospinal Fluid Proteins; Epil | 1988 |